United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market by Treatment Type (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiester Type 4 Inhibitor, Mucokinetics, and Others), By Type (Chronic Bronchitis, and Emphysema), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028F

United Kingdom chronic obstructive pulmonary disease treatment market is anticipated to witness impressive growth during the forecast period. It can be ascribed to the growing demand for effective medications because it gives some health benefits such as improved lung function, reduced exacerbations, enhanced exercise capacity and reduced mortality risk along with growing demand for inhalation devices as daily routine for health benefits. Also, increasing demand for integrated care, disease management, and digital health solutions additives along with growing demand for effective medications and personalized treatment such as bronchodilators, inhaled corticosteroids, combination medications, diagnosis and disease severity, inhaler device selection, and lifestyle modifications is expected to create a lucrative growth of United Kingdom chronic obstructive pulmonary disease treatment market during the forecast period.

According to National Institutes of Health Each year, pneumonia is diagnosed in about 220,000 persons. Although some people acquire several diagnoses in one year, Also focused on the number of people who received a diagnosis rather than the number of cases. There is a high demand for effective medications that can alleviate symptoms, improve lung function, and reduce exacerbations in chronic obstructive pulmonary disease (COPD) patients. Bronchodilators, corticosteroids, and combination therapies are commonly prescribed to manage chronic obstructive pulmonary disease (COPD). Effective chronic obstructive pulmonary disease (COPD) medications help alleviate symptoms such as shortness of breath, coughing, and wheezing. By reducing airway inflammation and opening the air passages, medications can provide relief and improve the overall quality of life for chronic obstructive pulmonary disease (COPD) patients may contribute to United Kingdom chronic obstructive pulmonary disease treatment market growth.

Smoking and Pollution Drive the Market Growth

Smoking and pollution are significantly causing chronic obstructive pulmonary disease (COPD) treatment in the United Kingdom cigarette smoking is the main contributor of COPD. Only 10% of cases are non-smokers, although 10–20% of smokers will eventually get the disease 90% of cases of chronic obstructive pulmonary disease (COPD) is because of smoking. Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) in the UK and globally. The majority of chronic obstructive pulmonary disease (COPD) cases are directly linked to smoking cigarettes or other forms of tobacco use. In United Kingdom 13.3% of people 18 year and over smoked cigarettes which is 6.6 million peoples in the population. Smoking damages the airways and lung tissue, leading to inflammation, narrowing of the airways, and reduced lung function. Due to the strong association between smoking and chronic obstructive pulmonary disease (COPD), smoking cessation is a primary focus in COPD treatment. Healthcare providers emphasize the importance of quitting smoking to slow disease progression, alleviate symptoms, and reduce the risk of exacerbations. Smoking cessation interventions, such as counseling, nicotine replacement therapies, and medication assistance, are incorporated into chronic obstructive pulmonary disease (COPD) treatment plans. The MPOWER package is a set of evidence-based strategies developed by the WHO to support countries in implementing effective tobacco control measures. MPOWER stands for:

Monitor tobacco use and prevention policies, protect people from tobacco smoke, offer to help to quit tobacco use, warn about the dangers of tobacco, enforce bans on tobacco advertising, promotion, and sponsorship, and raise taxes on tobacco products.

By implementing these strategies, the MPOWER package aims to reduce tobacco use, encourage smoking cessation, and protect individuals from the harms of smoking.

Exposure to environmental pollutants, such as particulate matter, industrial emissions, and outdoor air pollution, can contribute to the development and exacerbation of chronic obstructive pulmonary disease (COPD). Poor air quality is a concern in certain regions of the UK, In London there are more than 500000 people who live with asthma with US AQI 68. especially in urban areas and locations with high industrial activity. This may anticipate in the growth of United Kingdom chronic obstructive pulmonary disease treatment market.

Growing COPD Prevalence Promise the Growth of Market

The growing prevalence of chronic obstructive pulmonary disease (COPD) in the United Kingdom is a significant driver for the COPD treatment market. As Chronic Obstructive Pulmonary Disease (COPD) becomes more prevalent, there is an increasing demand for effective treatments and therapies to manage the disease. According to NHS Digital data, 1.9% of the population in England had a COPD diagnosis in 2020–21, which is approximately 1.17 million people. The rising prevalence of chronic obstructive pulmonary disease (COPD) means a larger patient pool requiring treatment. Around 2% of the whole population, in which, 4.5% of people are over 40 years aged. Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease, and as the population ages and risk factors such as smoking and environmental pollution persist, the number of individuals with chronic obstructive pulmonary disease (COPD) continues to grow. This larger patient pool creates a demand for chronic obstructive pulmonary disease (COPD) treatments, driving the United Kingdom chronic obstructive pulmonary disease treatment market.

With the growing chronic obstructive pulmonary disease (COPD) prevalence, there is a need for diverse treatment and management options to address the varying needs of chronic obstructive pulmonary disease (COPD) patients. This drives research and development efforts to innovate and introduce new medications, inhalation devices, and therapeutic approaches. The availability of a wider range of treatment options allows healthcare providers to personalize care based on individual patient needs and preferences, which is driving the growth of United Kingdom chronic obstructive pulmonary disease treatment market.

Download Free Sample Report

Increasing Awareness and Diagnosis

Increasing awareness and diagnosis of chronic obstructive pulmonary disease (COPD) in the United Kingdom have a positive impact on the COPD treatment market. Improved awareness of chronic obstructive pulmonary disease (COPD) symptoms and risk factors encourages individuals to seek medical attention earlier, leading to earlier diagnosis and intervention. Timely diagnosis allows healthcare providers to initiate appropriate treatments and interventions, which can slow disease progression, improve symptom management, and enhance patient outcomes. Increased awareness and early diagnosis drive the demand for United Kingdom chronic obstructive pulmonary disease treatment market. Increasing awareness about COPD raises public consciousness about the disease and its impact on individuals' health. 1,170,437 individuals were diagnosed with chronic obstructive pulmonary disease (COPD), making it the 1.93% national prevalence. As a result, more individuals who were previously undiagnosed or underdiagnosed seek medical evaluation, leading to a larger patient pool. This expanding patient pool creates a greater demand for COPD treatments, driving the growth of the United Kingdom chronic obstructive pulmonary disease treatment market.

Recent Development

In 2022, Affinivax, Inc., a clinical-stage biopharmaceutical company, will be acquired by GSK for US$2.1 billion, plus up to US$1.2 billion in potential milestone payments. The most innovative vaccinations in this new class are next-generation pneumococcal vaccines, which are being developed by Affinivax.

In 2018, The consumer health operations of GlaxoSmithKline plc and Pfizer Inc will be united into a new, globally recognised joint venture with combined sales of about USD9.8 billion (USD12.7 billion). In the joint venture, GSK will hold a 68% majority controlling equity interest, while Pfizer will hold a 32% equity stake.

In October 2021, GSK has unveiled plans for a new consumer healthcare company's UK headquarters. In addition to its long-term plan for the GSK headquarters, GSK unveiled designs for a significant new UK-based headquarters and worldwide campus for the new Consumer Healthcare company following its separation in 2022.

Market Segmentation

The United Kingdom chronic obstructive pulmonary disease treatment market can be segmented by Treatment Type, Type, Distribution Channel and region. Based on Treatment Type, the market can be segmented into Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiester Type 4 Inhibitor, Mucokinetics, and Others. Based on Type, the market can be segmented into Chronic Bronchitis, and Emphysema. Based on Distribution Channel, the market can be grouped into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market can be grouped into Scotland, Southeast, London, Southwest, Yorkshire, and East Midlands

Market Players

GlaxoSmithKline (GSK) PLC, AstraZeneca Ltd, Boehringer Ingelheim GmbH, Novartis Ltd, Teva Pharmaceutical Industries Ltd., Orion Pharma Ltd, and Vectura Group Ltd/United Kingdom. are some of the leading players operating in the United Kingdom chronic obstructive pulmonary disease treatment market.

Report Scope:

In this report, the United Kingdom chronic obstructive pulmonary disease treatment market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market, By Treatment Type:

o      Combination Therapy

o      Bronchodilators

o      Corticosteroids

o      Phosphodiester Type 4 Inhibitor

o      Mucokinetics

o      Others

• United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market, By Type:

o      Chronic Bronchitis

o      Emphysema

• United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market, By Distribution Channel:

o      Hospital Pharmacies

o      Retail Pharmacies

o      Online Pharmacies

• United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market, By Region:

o      Scotland

o      South-East

o      London

o      South-West

o      Yorkshire & Humberside

o      East Midlands

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present United Kingdom chronic obstructive pulmonary disease treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United Kingdom chronic obstructive pulmonary disease treatment market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]